Verrica Pharmaceuticals Inc (VRCA) - News Archive

Restructuring for Resilience: Verrica Pharmaceuticals’ Strategic Public Offering Amid Market ChallengesIn the dynamic landscape of pharmaceuticals, strategic maneuvers are critical to ensuring sustainability and growth,...

In an eye-catching move aimed at recalibrating its strategic trajectory, Verrica Pharmaceuticals Inc. has recently announced a comprehensive restructuring of its commercial organization, a decision necessitated by a sob...

Positive Advances in Basal Cell Carcinoma Treatment: Verrica Pharmaceuticals VP-315 Shows Promising Results In an inspiring stride towards combating Basal Cell Carcinoma (BCC), Verrica Pharmaceuticals recently unveiled...

Verrica Pharmaceuticals, a dermatology therapeutics company, has recently announced a litigation settlement with Dormer Laboratories, Inc. The settlement has led to Dormer Labs discontinuing the sale of all cantharidin-...

In recent news, Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) finds itself under the scrutiny of Bragar Eagel & Squire, P.C., a well-respected shareholder rights law firm. The firm has initiated an investigation after th...

Verrica Pharmaceuticals Inc. has announced a significant amendment to its collaboration and license agreement with Japan-based Torii Pharmaceutical Co. Ltd. This strategic modification aims to fund and facilitate a glob...

Verrica Pharmaceuticals, a renowned pharmaceutical company, has recently announced that its product YCANTH has received the prestigious New Chemical Entity (NCE) status from the U.S. Food and Drug Administration (FDA)....

Verrica Pharmaceuticals, a leading dermatology therapeutics company, has recently received a significant milestone in its quest to provide medical interventions for skin diseases. The Centers for Medicare & Medicaid Ser...

Basal cell carcinoma (BCC) is the most common type of skin cancer, affecting millions of individuals each year in the United States alone. Despite its prevalence, there remains a significant unmet need for effective tre...

by In a recent announcement, Verrica Pharmaceuticals Inc. revealed that it has received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development of YCANTH f...

Verrica Pharmaceuticals Expands Distribution Network with Walgreens Specialty Pharmacy PartnershipWEST CHESTER, Pa., Jan. 03, 2024 - Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics compan...